Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427744 | 0.85 | SLC2A1 (0.52) | SLC2A1ALDH1A1GABRA2GABRB2PSMD14 | |
| SCHEMBL1428082 | 0.85 | KDM4E (0.60) | SLC2A1GABRB2 | |
| SCHEMBL1430426 | 0.74 | SLC2A1 (0.59) | SLC2A1ALDH1A1GABRA2GABRB2CYP1A2 | |
| SCHEMBL1430894 | 0.74 | SLC2A1 (0.54) | SLC2A1ALDH1A1GABRA2GABRB2PSMD14 | |
| Hydrochloric Acid SCHEMBL1430111 | 0.73 | SLC2A1 (0.58) | SLC2A1ALDH1A1GABRA2GABRB2CYP1A2 | |
| Hydrochloric Acid SCHEMBL1431028 | 0.71 | SLC2A1 (0.62) | SLC2A1ALDH1A1GABRA2GABRB2SLC2A2 | |
| SCHEMBL2222798 | 0.70 | SLC2A1 (0.61) | SLC2A1ALDH1A1GABRA2GABRB2MEN1 | |
| SCHEMBL1428245 | 0.70 | KDM4E (0.60) | SLC2A1GABRB2KMT2A | |
| SCHEMBL1433233 | 0.69 | SLC2A1 (0.60) | SLC2A1ALDH1A1GABRA2GABRB2CYP1A2 | |
| SCHEMBL12128935 | 0.69 | CYP1A2 (0.59) | SLC2A1ALDH1A1GABRA2GABRB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2300470-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS GABA-A RECEPTOR MODULATORS | Sepracor Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009143156-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SEPRACOR INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | SLC2A1 2033/4885ALDH1A1 269/4885GABRA2 794/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | SLC2A1 2033/4885ALDH1A1 269/4885GABRA2 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.